OrbiMed’s Olema Pharmaceuticals OLMA Stock Holding History

OrbiMed’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-807,792	Closed	-$22.3M	–	171
2021 Q3	$22.3M	Hold	807,792	–	–	0.24%	92
2021 Q2	$22.6M	Buy	807,792 +151,666	+23%	+$4.32M	0.23%	93
2021 Q1	$21.8M	Buy	656,126 +5,134	+0.8%	+$220K	0.2%	97
2020 Q4	$31.3M	Buy	+650,992	New	+$30.5M	0.27%	81

Other funds holding OLMA

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

OrbiMed's OLMA Position: Q4 2021 in Review

OrbiMed sold out of Olema Pharmaceuticals (OLMA) in Q4 2021, closing a stake of 807,792 shares — an estimated $22.3M sold.

OrbiMed first reported a position in OLMA in Q4 2020 and held it in 4 quarters. The position peaked at $31.3M in Q4 2020. 97 funds tracked by Wall St. Rank hold OLMA as of Q4 2021.

OrbiMed reported no remaining Olema Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
OrbiMed sold 807,792 Olema Pharmaceuticals shares in Q4 2021, an estimated $22.3M.
OrbiMed first reported a position in Olema Pharmaceuticals in Q4 2020 and held it in 4 quarters.
OrbiMed's Olema Pharmaceuticals position peaked at $31.3M in Q4 2020.
97 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2021.

Based on OrbiMed's 13F filing for Q4 2021, filed 14 Feb 2022.